FDA- Approves Pembrolizumab With Chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma
FDA批准了帕博利珠單抗聯合化療用於原發性晚期或複發性子宮內膜癌
FDA- Approves Pembrolizumab With Chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma
FDA批准了帕博利珠單抗聯合化療用於原發性晚期或複發性子宮內膜癌
譯文內容由第三人軟體翻譯。